Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA, RESILIENT Study Group

Open source

DOI
10.1016/s1474-4422(19)30200-5
Published
2019 Sep
Container
The Lancet. Neurology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-19-30200-5,
  title = {Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.},
  author = {Hanna MG and Badrising UA and Benveniste O and Lloyd TE and Needham M and Chinoy H and Aoki M and Machado PM and Liang C and Reardon KA and de Visser M and Ascherman DP and Barohn RJ and Dimachkie MM and Miller JAL and Kissel JT and Oskarsson B and Joyce NC and Van den Bergh P and Baets J and De Bleecker JL and Karam C and David WS and Mirabella M and Nations SP and Jung HH and Pegoraro E and Maggi L and Rodolico C and Filosto M and Shaibani AI and Sivakumar K and Goyal NA and Mori-Yoshimura M and Yamashita S and Suzuki N and Katsuno M and Murata K and Nodera H and Nishino I and Romano CD and Williams VSL and Vissing J and Auberson LZ and Wu M and de Vera A and Papanicolaou DA and Amato AA and RESILIENT Study Group},
  year = {2019},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(19)30200-5},
  url = {https://doi.org/10.1016/s1474-4422(19)30200-5}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
AU  - Hanna MG
AU  - Badrising UA
AU  - Benveniste O
AU  - Lloyd TE
AU  - Needham M
AU  - Chinoy H
AU  - Aoki M
AU  - Machado PM
AU  - Liang C
AU  - Reardon KA
AU  - de Visser M
AU  - Ascherman DP
AU  - Barohn RJ
AU  - Dimachkie MM
AU  - Miller JAL
AU  - Kissel JT
AU  - Oskarsson B
AU  - Joyce NC
AU  - Van den Bergh P
AU  - Baets J
AU  - De Bleecker JL
AU  - Karam C
AU  - David WS
AU  - Mirabella M
AU  - Nations SP
AU  - Jung HH
AU  - Pegoraro E
AU  - Maggi L
AU  - Rodolico C
AU  - Filosto M
AU  - Shaibani AI
AU  - Sivakumar K
AU  - Goyal NA
AU  - Mori-Yoshimura M
AU  - Yamashita S
AU  - Suzuki N
AU  - Katsuno M
AU  - Murata K
AU  - Nodera H
AU  - Nishino I
AU  - Romano CD
AU  - Williams VSL
AU  - Vissing J
AU  - Auberson LZ
AU  - Wu M
AU  - de Vera A
AU  - Papanicolaou DA
AU  - Amato AA
AU  - RESILIENT Study Group
PY  - 2019
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(19)30200-5
UR  - https://doi.org/10.1016/s1474-4422(19)30200-5
ER  -

APA

MG, H., UA, B., O, B., TE, L., M, N., H, C., M, A., PM, M., C, L., KA, R., M, D. V., DP, A., RJ, B., MM, D., JAL, M., JT, K., B, O., NC, J., P, V. D. B., J, B., JL, D. B., C, K., WS, D., M, M., SP, N., HH, J., E, P., L, M., C, R., M, F., AI, S., K, S., NA, G., M, M., S, Y., N, S., M, K., K, M., H, N., I, N., CD, R., VSL, W., J, V., LZ, A., M, W., A, D. V., DA, P., AA, A., & Group, R. S. (2019). Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(19)30200-5

Source records